Bicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Bicycle Therapeutics plc (NASDAQ:BCYC) has earned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $33.25.

A number of equities research analysts recently issued reports on BCYC shares. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Bicycle Therapeutics in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating and set a $33.00 target price on shares of Bicycle Therapeutics in a research report on Monday, January 13th. B. Riley dropped their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Finally, JMP Securities lowered their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th.

Insider Buying and Selling

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 2,686 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the transaction, the chief accounting officer now directly owns 32,146 shares in the company, valued at $482,190. This represents a 7.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Alistair Milnes sold 4,578 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $64,504.02. Following the sale, the chief operating officer now directly owns 100,724 shares of the company’s stock, valued at $1,419,201.16. This represents a 4.35 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 27,677 shares of company stock valued at $392,413. Insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Westfield Capital Management Co. LP lifted its holdings in shares of Bicycle Therapeutics by 21.5% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock worth $41,887,000 after buying an additional 327,089 shares during the period. Candriam S.C.A. raised its holdings in shares of Bicycle Therapeutics by 3.5% in the fourth quarter. Candriam S.C.A. now owns 1,087,876 shares of the company’s stock valued at $15,230,000 after acquiring an additional 37,278 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in Bicycle Therapeutics by 1,438.1% in the third quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock worth $20,362,000 after acquiring an additional 841,299 shares during the period. Principal Financial Group Inc. bought a new position in Bicycle Therapeutics during the 3rd quarter worth about $10,028,000. Finally, Handelsbanken Fonder AB increased its position in Bicycle Therapeutics by 2.4% during the 3rd quarter. Handelsbanken Fonder AB now owns 218,700 shares of the company’s stock valued at $4,949,000 after purchasing an additional 5,200 shares during the period. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Price Performance

Shares of BCYC opened at $11.84 on Tuesday. The stock has a market capitalization of $817.50 million, a price-to-earnings ratio of -3.60 and a beta of 0.93. Bicycle Therapeutics has a 1 year low of $11.77 and a 1 year high of $28.67. The business’s 50 day simple moving average is $14.89 and its 200-day simple moving average is $20.43.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.